ID   BE(2)-C/CHCg
AC   CVCL_V010
DR   Wikidata; Q54795870
RX   PubMed=8660514;
CC   Population: Caucasian.
CC   Characteristics: Intermediate type (I-type) (from parent cell line).
CC   Characteristics: MYCN-amplified NBL cell line (from parent cell line).
CC   Selected for resistance to: ChEBI; CHEBI:23359; Colchicine.
CC   Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Heterozygous (from parent cell line).
CC   Derived from metastatic site: Bone marrow.
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0529 ! SK-N-BE(2)-C
SX   Male
AG   2Y2M
CA   Cancer cell line
DT   Created: 16-04-14; Last updated: 23-06-22; Version: 14
//
RX   PubMed=8660514; DOI=10.1006/abio.1996.0176;
RA   Levchenko A., Mehta B.M., Spengler B.A., Narkar A.A., Fonti R.,
RA   Biedler J.L., Tsuruo T., Larson S.M.;
RT   "Measurement of P-glycoprotein expression in multidrug-resistant human
RT   neuroblastoma cell lines using self-competitive binding assay.";
RL   Anal. Biochem. 236:338-343(1996).
//